Search results for "ORPHAN DRUG|Designated|Treatment of chronic myelogenous leukemia" in comments (approximate match)
Showing 1 - 6 of 6 results
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Nilotinib (AMN107, trade name Tasigna) is a kinase inhibitor indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior ...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Tanespimycin (17-allylamino-17-demethoxygeldanamycin,
17-AAG) is a synthetic analogue of geldanamycin, an antibiotic
first purified in 1970 from Streptomyces hygroscopicus. Tanespimycin is an Hsp90 inhibitor that has demonstrated the potential to dis...
NRC-AN-019 has been found to be a promising new lead compound for the therapy of imatinib mesylate-resistant chronic myeloid leukemia. NRC-AN-019 showed considerable safety and response. In addition, it has the therapeutic potential in the treatment ...
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Dasatinib [BMS 354825] is an orally active, small molecule, dual inhibitor of both SRC and ABL kinases that is under development with Bristol-Myers Squibb for the treatment of patients with chronic myelogenous leukaemia (CML) and imatinib-acquired re...